The growzen™ buddy smartphone app to improve adherence in patients receiving recombinant human growth hormone therapy: a retrospective observational study in Argentina.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as an observational study.

This study in Argentina evaluated the impact of the growzen™ buddy smartphone app on adherence to recombinant human growth hormone (r-hGH) treatment.

Who Took Part

The age groups tagged for this paper are young children, children, teenagers, young adults and adults, both men and women.

The adherence data, invitation dates with a link to the app, app activation dates, and height measurements entered were extracted from the growzen™ digital health ecosystem.

Patients with 12 months of adherence data, aged ≥2 years at treatment start, and aged <19 years were selected both before and after app implementation.

How the Study Was Run

Adherence before and after implementation and the pre-post effect on adherence were assessed.

What Was Measured

This study in Argentina evaluated the impact of the growzen™ buddy smartphone app on adherence to recombinant human growth hormone (r-hGH) treatment.

PubMed files the paper under topics including Mobile Applications, Argentina, Smartphone, Human Growth Hormone, Recombinant Proteins and Drug Monitoring.

The authors tagged it with the keywords growth disorders, growzen, patient support program and recombinant human growth hormone.

What This Means in Plain Language

This is an observational study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (Frontiers in endocrinology), a journal based in Switzerland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.